Back

Alzheimer/Dementia

Studies

• The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
• Endocannabinoid signalling in Alzheimer’s disease
• A molecular link between the active component of marijuana and Alzheimer’s disease pathology
• Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells
• The Potential Therapeutic Effects of THC on Alzheimer’s Disease
• The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease 
• CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression 
• CBD: A promising drug for neurodegenerative disorders?
• Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
• The role of the endocannabinoid system in Alzheimer’s disease
• The role of phytochemicals in the treatment and prevention of dementia
• Cannabinoids for the treatment of dementia
• Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression inSHSY5YAPP+ Cells Through PPARγ Involvement
• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
• Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia
• Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
• Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
• Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model
• CBD Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
• In vivo Evidence for Therapeutic Properties of CBD for Alzheimer’s Disease
• Neurological aspects of medical use of CBD
• Amyloid-beta inhibits E-S Potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition
• Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids
• Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease
• Alzheimer’s disease; taking the edge off with cannabinoids?
• Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
• Cannabinoids and Parkinson’s disease
• Cannabinoids for the treatment of agitation and aggression in Alzheimer’s disease
• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
• Cannabinoids for the treatment of dementia
• Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease
• CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease
• Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice
• Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
• Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
• Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
• Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation
• Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study
• Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease
• Synthetic cannabinoids in dementia with agitation: Case studies and literature review
• The influence of cannabinoids on generic traits of neurodegeneration
• The potential therapeutic effects of THC on Alzheimer’s disease
• The role of the endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease